Robin is a board director of Pfenex (PFNX), Inc. He has more than 30 years of experience in biopharma product development and R&D management, including 13 years at Amgen. While at Amgen, Robin served as the VP and General Manager of the Oncology Business Unit.
For nearly a decade, Scott has driven the realization of innovative solutions to major problems in health care. As CEO, he leverages his training in management and engineering science to develop and execute the corporate vision and strategy. To bring Aptitude's transformative value to market, Scott is responsible for customer development and strategic partnerships with industry leaders.
Prior to Aptitude, Scott has played an active role in multiple technology ventures including Cynvenio Biosytems, Ruubix, and Life Cube. He has pioneered technologies for personalized medicine and point of care diagnostics, authoring multiple patents, and peer-reviewed journal publications.
Trained in both life science research and management, Jackson brings to Aptitude both scientific and operational expertise. He has published 10+ peer-reviewed papers and co-invented several patents that serve as the foundation of Aptitude technology.
In Aptitude, Jackson oversees business development and external innovation.
JP has focused his career on applying engineering principles to biological problems that promote scientific discovery and the development of new biomedical technologies and therapies. While pursuing his Ph.D. at the University of California, Santa Barbara, he has authored multiple peer-reviewed journal publications, and is the lead inventor of Aptitude’s revolutionary aptamer discovery technology.
As CTO, JP shapes the company’s technical vision and R&D strategy, while overseeing internal R&D programs, establishing R&D collaborations, and leading the team of scientists.
Our technology originates from Professor H. Tom Soh's lab. Dr. Soh is a professor at Stanford University and a Chan Zuckerberg Biohub Investigator. The technical leadership of the Soh Lab has been demonstrated in >100 publications, and highlighted by Nature SciBX, Nature News and Views, Science Now, Nature Medicine. Prof. Soh has attracted over $20 M in funding from the NIH, DARPA, Keck Foundation, DOD, CIRM, and collaborations with leading pharmaceutical companies.